儿童B细胞前体急性淋巴细胞白血病驱动突变图谱及其临床影响
该研究对来自2个日本队列的1003例儿童B-ALL患者进行靶向捕获测序,并对203例未分型患者补充转录组测序和/或基因表达分析。发现CCND3和CIC为新发反复突变基因,多因素分析显示TP53突变/缺失、低二倍体和MEF2D融合与总生存不良相关,TP53突变在NCI标危患者中不影响预后。
要点
- TP53突变/缺失、低二倍体和MEF2D融合是儿童B-ALL总生存的独立不良因素。
- TP53突变在NCI标危患者中与不良预后无关,常规治疗可能已足够。
- CCND3和CIC为新发现的反复突变基因,分别与ETV6-RUNX1和低二倍体ALL正相关。
核心结论
- TP53突变/缺失、低二倍体和MEF2D融合在2个队列中均被多因素Cox模型选为总生存的独立预后因素。
- TP53突变对总生存的负面影响在独立外部队列(n=466)中得到验证。
- TP53突变在NCI标危患者中与不良预后无关,常规治疗可能足够,无需进一步强化治疗。
研究设计与样本
- 对来自2个日本队列的共1003例儿童B-ALL患者进行靶向捕获测序。
- 对243例经panel测序或常规RT-PCR未分型患者中的203例(84%)进行转录组测序(n=116)和/或基于芯片的基因表达分析(n=120)。
- 使用多因素Cox比例风险回归模型分析总生存,并在独立外部队列(n=466)中验证TP53突变的预后影响。
主要发现
- panel测序鉴定出CCND3和CIC两个基因的新发反复突变,分别与ETV6-RUNX1和低二倍体ALL正相关。
- 新报道TCF3-PBX1 ALL与PHF6突变正相关。
- TP53突变在IGH-DUX4 ALL中频繁出现(57例中5例[9%]),其中4例伴有17p LOH,并负向影响该亚组总生存。
- TP53突变在NCI标危患者中与不良预后无关。
关键数值与推荐
- TP53突变/缺失、低二倍体和MEF2D融合在2个队列的多因素Cox模型中均被选为总生存的预后因素。
- TP53突变对总生存的负向效应在独立外部队列(n=466)中得到确认。
- TP53突变在IGH-DUX4 ALL中发生率为5/57(9%),其中4例有17p LOH。
临床怎么用
- 对儿童B-ALL应检测TP53突变/缺失、低二倍体和MEF2D融合以进行预后分层。
- NCI标危且伴TP53突变的患者可能无需强化治疗,常规方案可能已足够。
- IGH-DUX4 ALL亚组中TP53突变需关注,尤其伴17p LOH者可能预后不良。
局限性
- 研究基于日本队列,结论外推需谨慎。
- 转录组测序和基因表达分析仅覆盖部分未分型患者(203/243,84%)。
- TP53突变在NCI标危患者中的预后结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent genetic studies using high-throughput sequencing have disclosed genetic alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects on clinical outcomes have not been fully investigated. To address this, we comprehensively examined genetic alterations and their prognostic impact in a large series of pediatric B-ALL cases. We performed targeted capture sequencing in a total of 1003 pediatric patients with B-ALL from 2 Japanese cohorts. Transcriptome sequencing (n = 116) and/or array-based gene expression analysis (n = 120) were also performed in 203 (84%) of 243 patients who were not categorized into any disease subgroup by panel sequencing or routine reverse transcription polymerase chain reaction analysis for major fusions in B-ALL. Our panel sequencing identified novel recurrent mutations in 2 genes (CCND3 and CIC), and both had positive correlations with ETV6-RUNX1 and hypodiploid ALL, respectively. In addition, positive correlations were also newly reported between TCF3-PBX1 ALL with PHF6 mutations. In multivariate Cox proportional hazards regression models for overall survival, TP53 mutation/deletion, hypodiploid, and MEF2D fusions were selected in both cohorts. For TP53 mutations, the negative effect on overall survival was confirmed in an independent external cohort (n = 466). TP53 mutation was frequently found in IGH-DUX4 (5 of 57 [9%]) ALL, with 4 cases having 17p LOH and negatively affecting overall survival therein, whereas TP53 mutation was not associated with poor outcomes among NCI (National Cancer Institute) standard risk (SR) patients. A conventional treatment approach might be enough, and further treatment intensification might not be necessary, for patients with TP53 mutations if they are categorized into NCI SR.
引用
- Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020. PMID: 33095873. doi:10.1182/bloodadvances.2019001307
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。